<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085228</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-30021</org_study_id>
    <secondary_id>EORTC-30021</secondary_id>
    <secondary_id>AVENTIS-AVE3139E/2501</secondary_id>
    <nct_id>NCT00085228</nct_id>
  </id_info>
  <brief_title>Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate</brief_title>
  <official_title>Randomized Phase II Trial of Docetaxel (Taxotere) and Oblimersen (Antisense Oligonucleotide Directed to BCL-2) Versus Taxotere Alone in Patients With Hormone-Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Oblimersen may increase the&#xD;
      effectiveness of docetaxel by making tumor cells more sensitive to the drug.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well giving docetaxel together with&#xD;
      oblimersen works compared to docetaxel alone in treating patients with hormone-refractory&#xD;
      adenocarcinoma (cancer) of the prostate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the activity of docetaxel with or without oblimersen, in terms of&#xD;
           prostate-specific antigen response, in patients with hormone-refractory adenocarcinoma&#xD;
           of the prostate.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the time to progression in patients treated with these regimens.&#xD;
&#xD;
        -  Compare survival of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center, metastatic disease (M0 vs M1 with non-measurable lesions only vs M1&#xD;
      with measurable lesions), prior estramustine (yes vs no), and prior bisphosphonates (yes vs&#xD;
      no). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive docetaxel IV over 1 hour on day 5 and oblimersen IV continuously&#xD;
           on days 1-7.&#xD;
&#xD;
        -  Arm II: Patients receive docetaxel IV over 1 hour on day 1. In both arms, treatment&#xD;
           repeats every 21 days for up to 12 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 8 weeks until progressive disease and then every 16 weeks&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 102 patients (51 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate-specific antigen response as measured by Bubley criteria every course until progression or after 12 courses</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe toxic events as measured by CTCAE v3.0 every course until progression or after 12 courses</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression as measured by RECIST and Bubley criteria every 3 courses, and then every 8 weeks until progression, and every 16 weeks from progression until death</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by CTCAE v3.0 every 3 courses, and then every 8 weeks until progression, and every 16 weeks from progression until death</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response as measured by RECIST every 3 courses, and then every 8 weeks until progression, and every 16 weeks from progression until death</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival as measured by Logrank every 3 courses, and then every 8 weeks until progression, and every 16 weeks from progression until death</measure>
  </secondary_outcome>
  <enrollment type="Actual">116</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oblimersen sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Hormone-refractory disease&#xD;
&#xD;
               -  Disease progression after prior hormonal therapy with luteinizing&#xD;
                  hormone-releasing hormone (LH-RH) analogues or orchiectomy and antiandrogens&#xD;
                  (given together or consecutively)&#xD;
&#xD;
          -  Prostate-specific antigen (PSA) progression documented by at least 2 increases in PSA&#xD;
             values over previous PSA reference value&#xD;
&#xD;
               -  Must demonstrate continued PSA elevation for at least 6 weeks after&#xD;
                  discontinuation of antiandrogen therapy&#xD;
&#xD;
          -  PSA ≥ 5 ng/mL (Hybritech or equivalent) within the past week&#xD;
&#xD;
          -  Testosterone ≤ 0.5 ng/mL* NOTE: *Patients with medical castration with LH-RH analogue&#xD;
             must continue with LH-RH analogue throughout the study&#xD;
&#xD;
          -  No evidence of painful and/or destructive bone metastases requiring concurrent&#xD;
             radiotherapy, bisphosphonates, or bone-seeking radionuclides&#xD;
&#xD;
               -  Other bone metastases allowed&#xD;
&#xD;
          -  No clinical evidence of brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ ULN&#xD;
&#xD;
          -  PTT and PT ≤ 1.5 times ULN OR&#xD;
&#xD;
          -  INR ≤ 1.3&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No deep venous thrombosis within the past 6 months&#xD;
&#xD;
          -  No cerebrovascular accident, transient ischemic attack, or myocardial infarction&#xD;
             within the past 6 months&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pulmonary embolism&#xD;
&#xD;
          -  No history of interstitial pneumonitis&#xD;
&#xD;
          -  No history of pulmonary fibrosis&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Adequate venous access&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No pre-existing neuropathy&#xD;
&#xD;
          -  No hypersensitivity to phosphorothioates&#xD;
&#xD;
          -  No hypersensitivity to oligonucleotides or any other component of the oblimersen&#xD;
             formulation or to drugs formulated with polysorbate&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated superficial&#xD;
             urothelial or skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior estramustine allowed&#xD;
&#xD;
          -  No other prior chemotherapy&#xD;
&#xD;
          -  No concurrent estramustine&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 weeks since prior flutamide, bicalutamide, or nilutamide&#xD;
&#xD;
          -  More than 6 weeks since prior hormonal manipulation with PC-SPES&#xD;
&#xD;
          -  Concurrent LH-RH agonist allowed&#xD;
&#xD;
          -  No concurrent antiandrogens&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiotherapy involving &gt; 25% of marrow-producing area&#xD;
&#xD;
          -  No prior bone-seeking radionuclides&#xD;
&#xD;
          -  No concurrent radiotherapy (including palliative therapy for painful bone metastases)&#xD;
&#xD;
          -  No concurrent bone-seeking radionuclides&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Prior bisphosphonates allowed&#xD;
&#xD;
          -  No concurrent anticoagulation except for low-dose warfarin (1 mg/day)&#xD;
&#xD;
          -  No concurrent regular (daily) intake of opioid analgesics&#xD;
&#xD;
          -  No other concurrent experimental drugs or anticancer drugs&#xD;
&#xD;
          -  No concurrent bisphosphonates&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cora N. Sternberg, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedaliera S. Camillo-Forlanini</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Franz Josef Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>B-9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet - Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hopital de la Tronche</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Camillo-Forlanini</name>
      <address>
        <city>Rome</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Desterro</name>
      <address>
        <city>Lisboa</city>
        <zip>2700</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, Sella A, Daugaard G, Gil T, Graham J, Carpentier P, Calabro F, Collette L, Lacombe D; EORTC Genitourinary Tract Cancer Group. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol. 2009 Jul;20(7):1264-9. doi: 10.1093/annonc/mdn784. Epub 2009 Mar 17.</citation>
    <PMID>19297314</PMID>
  </results_reference>
  <results_reference>
    <citation>Sternberg CN, Dumez H, Van Poppel H, et al.: Multicenter randomized EORTC trial 30021 of docetaxel + oblimersen and docetaxel in patients (pts) with hormone refractory prostate cancer (HRPC). [Abstract] American Society of Clinical Oncology 2007 Prostate Cancer Symposium, 22-24 February 2007, Orlando, FL. A-144, 2007.</citation>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oblimersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

